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Purpose:To assess clinical outcomes and toxicities in patients with stage III unresectable
non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofraction-
ated radiotherapy delivered with Helical Intensity-ModulatedTechnique in combination with
sequential or concurrent chemotherapy.
Materials and Methods: Sixty-one consecutive patients considered non-progressive after
two cycles of induction chemotherapy were treated with a moderately escalated hypofrac-
tionated radiation course of 30 daily fractions of 2.25–2.28 Gy each administered in 6 weeks
up to a total dose of 67.5–68.4 Gy (range, 64.5–71.3 Gy). Thirty-two received sequential RT
after two more cycles (total=4 cycles) of chemotherapy, while 29 were treated with concur-
rent chemo-radiation.The target was considered the gross tumor volume and the clinically
proven nodal regions, without elective nodal irradiation.
Results:With a median follow up of 27 months (range 6–40), 1-year and 2-year OS rate for
all patients was 77 and 53%, respectively, with a median survival duration of 18.6 months
in the sequential group and 24.1 months in the concomitant group. No Grade≥4 acute and
late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in
10% of patients.Two patients, both receiving the concurrent schedule, developed a Grade
3 acute esophagitis.The overall incidence of late Grade 3 lung toxicity was 5%. No patients
experienced a Grade 3 late esophageal toxicity.
Conclusion: A moderately hypofractionated radiation course delivered with a Helical
Intensity-ModulatedTechnique is a feasible treatment option for patients with unresectable
locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofrac-
tionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing
the effect of tumor repopulation that may occur with prolonged treatment time.
Keywords: dose escalation, hypofractionated radiotherapy, chemo-radiation, unresectable NSCLC, helical
tomotherapy
INTRODUCTION
More than two third of the patients with non-small-cell lung
cancer (NSCLC) in the Western Countries are found to have
locally advanced or metastatic disease at the time of diagnosis (1).
Improving outcomes for patients with stage III disease still remains
a major challenge. Concurrent chemo-radiation is the current
mainstay of treatment for unresectable NSCLC, since two meta-
analyses have confirmed the benefit of concomitant approach
using platinum-based therapy (2, 3). Nevertheless, local control is
achieved in 40% and 5-year survival is 15%. Other than systemic
failures, these poor clinical results can be partly attributed to the
still high rates of thoracic failures with traditional radiation doses
and techniques that cannot allow to deliver the radiation doses
beyond a certain threshold in order to avoid the risk of unaccept-
able toxicities. Indeed, while huge research have been devoted on
improving systemic therapy options for patients with advanced
lung cancer, less efforts have been placed on the importance of
increasing the delivered radiation dose beyond 60 Gy, which has
been the standard for over 20 years (4). Martel et al. (5) at the end
of 1990s estimated that the dose to achieve a 50% local control at
2 years should be above 70 Gy. Soon after, improvements in radi-
ation delivery techniques that have the potential to better sparing
of normal tissues as well as advances in tumor volume definition
have focused the attention in the investigation of dose escalation.
By using a conventional fractionation regimen, however, dose esca-
lation is obtained by increasing the number of daily treatments,
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thus resulting in a prolongation of the overall time. Unfortunately
in NSCLC such a long duration of the radiation course has been
shown to be detrimental to tumor control and survival, resulting
in a significantly shortened survival (p= 0.016) in four Radia-
tion Therapy Oncology Group (RTOG) prospective randomized
trials (6), with a loss of survival rate of 1.6% per day of prolonga-
tion beyond 6 weeks (7). Therefore, both total radiation dose and
treatment duration (or overall time) should be considered crucial
factors affecting the outcome of radiotherapy in the management
of NSCLC. Relying on a better conformal avoidance of normal
healthy tissues obtained with image-guided rotational IMRT (8),
we applied an alternative strategy that has already been shown (9)
to effectively escalate the dose by increasing dose per day while
reducing the number of treatment fractions and duration of the
treatment course, thus avoiding the risk of lessening the benefit of
the extra dose due to tumor cell repopulation during treatment (6,
10). In this article we retrospectively analyzed data from 61 con-
secutive patients with stage III unresectable NSCLC treated with
a moderately escalated hypofractionated radiotherapy delivered
with Helical Intensity-Modulated Technique in combination with
sequential or concurrent chemotherapy.
MATERIALS AND METHODS
POPULATION
The analysis included 61 patients with stage III unresectable
NSCLC who were considered non-progressive after two cycles of
induction platinum-based chemotherapy, basing on a contrast-
enhanced computed tomography (CT) scan of the chest,brain,and
upper abdomen. The treatment policy was reviewed and approved
by the IRB and carried out in compliance with the Helsinki Dec-
laration of 1975, as revised in 2000. Written informed consent was
obtained from each patient.
PRETREATMENT EVALUATION
Initial workup included bronchoscopy, CT of the lung and upper
abdomen through the adrenal glands, an MRI of the brain
with contrast, and a bone scan. A whole body 18F-deoxyglucose
(FDG) – Positron Emission Tomography (PET) scan was per-
formed in 33 patients (54%). All patients had a Forced Expiratory
Volume in the first second (FEV1) and DLCO (Carbon Monox-
ide Diffuse Capacity) at least 40% of predicted value, adequate
blood tests, consisting in absolute neutrophil count >1500/mL,
hemoglobin count ≥10 g/dL, platelet count ≥100,000/mL, serum
creatinine level <1.6 mg/dL, serum bilirubin <1.5 times normal
institutional limits, serum aspartate aminotransferase, and alanine
aminotransferase <2.5 normal institutional limits, and a World
Health Organization Performance Status (WHO-PS) ≤2. None
of them experienced a weight loss of more than 10% in the last
6 months.
TREATMENT
Treatment plan – chemotherapy
Induction chemotherapy consisted or cisplatin (80 mg/m2) or car-
boplatin (AUC 5) on day 1 and gemcitabine 1250 mg/m2 on day 1
and 8, for a total of two cycles repeated every 21 days. Thereafter,
patients candidates for chemo-radiotherapy with curative intent
were those considered non-progressive (RECIST criteria) (11).
In a first phase, the treatment schedule consisted in a sequential
approach, with radiation course intended to start at the end of two
more cycles of chemotherapy following the same rules described
above, within 7 days from day 21 of the cycle 4. After a first
report (12) showing only minor complications,all non-progressive
patients after induction chemotherapy were treated with con-
current chemoradiation. In the concurrent schedule cisplatin-
vinorelbine (cisplatin 40 mg/m2 day 2 and 9,vinorelbine 15 mg/m2
day 2 and 9, cisplatin 40 mg/m2 day 23, vinorelbine 15 mg/m2 day
23 and 30) was used, and radiotherapy began within 7 days after
the completion of induction chemotherapy (within 7 days from
day 21 of the cycle 2).
Treatment plan – radiotherapy
Simulation. All patients were positioned supine on a wing board
and immobilized by means of thermoplastic frames. CT scan for
planning from the level of the cricoid cartilage through the whole
liver volume was acquired in shallow breathing mode at 3 mm slice
thickness, ensuring that the amplitude of respiration, that was
checked under fluoroscopy, was kept within maximum 15 mm.
The gross tumor volume (GTV) included the primary tumor and
the pretreatment involved lymph nodes as defined on CT imaging
(short axis>1 cm or necrosis) or on FDG-PET. For the clinical tar-
get volume (CTV) a margin of 5 mm incorporating microscopic
disease around GTV was used (13). Depending on the tumor loca-
tion, the planning target volume (PTV) included the CTV plus a
total margin of at least 1 cm to the superior-inferior dimensions
and at least 0.8 cm in the axial plane, unless the PTV expansion
extended outside of the skin, or into the spinal canal. In this case,
PTV margins were limited. Automatic contouring of the lungs
and heart was performed using the Pinnacle3 treatment planning
system (version 8.0 h; Philips Radiation Oncology Systems, Fitch-
burg, MA, USA), with manual corrections allowed. Planning risk
volumes (PRV) were constructed with a 3-mm margin for the
spinal cord and 5-mm for the esophagus.
Dose schedule, constraints, and treatment delivery. Dose pre-
scription to the median dose point of the entire PTV was 30
fractions of 2.25–2.28 Gy each up to a total dose of 67.5–68.4 Gy
(range, 64.5–71.3 Gy). According to the linear-quadratic model,
the corresponding normalized total dose at 2 Gy per fraction
(EQD2) is approximately 70 and 72 Gy, considering an alfa/beta
ratio of 10 Gy for tumor and acutely responding normal tissues
and 3 Gy for late complications, respectively. The optimization was
driven with the aim of delivering the prescribed dose to at least
95% of the PTV, according to ICRU 50/62 guidelines (14). DVH’s
points and penalties were setted to best meet the constraints for
organs at risk (OARs) without compromising PTV coverage. Spe-
cific dosimetric guidelines for OARs in accordance to the Quantec
(15) dose-volume model were applied and rescaled on fractiona-
tion’s change as follows: V19 for lungs <30%, MLD (volume of
both lungs minus GTV)<19 Gy; a maximal dose (Dmax) of 47 Gy
on the spinal cord; mean esophageal volume <32 Gy, V33 <50%,
V47 <40%; mean heart volume <33 Gy, V38 <80%, V57 <30%.
Dose computation and treatment delivery were performed on
the TomoTherapy HiArt II system (TomoTherapy Inc., Madison,
WI, USA). Image-Guided Radiotherapy (IGRT) was performed
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by means of a Megavolt Computed Tomography (MVCT) before
each daily session in the same shallow breathing modality adopted
on CT simulation, and positioning was done using the integrated
registration with the planning CT to account for set-up uncer-
tainties. The delivery parameters usually used for treatment plan-
ning and optimization were: 2.5 cm (field width); 0.287 (pitch);
2.5 (modulation factors); 0.215 cm× 0.215 cm; (dose calculation
grid). Treatment replanning was never performed considering
that tumor shrinkage during the radiation course is small and
might be counteracted by the risk of delivering inadequate dose
to the tumor rind, where residual cancer clonogens may still be
present (16).
RESPONSE AND TOXICITY EVALUATION
Patients were seen weekly during treatment and at a 3-monthly
interval during the first 2 years of follow up and every 6 months
thereafter. Toxicity monitoring was focused on treatment-related
esophageal and pulmonary adverse events and assessed by the
RTOG grading system (17). Any increase in grade form baseline
was considered toxicity related to the treatment and calculated
for the acute (90 days from start of RT) and late phase (beyond
90 days). Assessment of tumor response relied upon RECIST cri-
teria (11). Progressive disease that developed within or at the
margin of the PTV, as well as recurrences in another lobe of the
ipsilateral lung, was scored as loco-regional failure, whereas pro-
gression in the contralateral lung or extrathoracic sites was defined
as distant failure. Overall survival was calculated by the Kaplan–
Meier method from the initiation of treatment and patients were
censored at the time of the specific event.
RESULTS
This report includes 61 enrolled patients with locally advanced
stage III unresectable NSCLC treated between 2008 and 2011,
with a median follow up of 27 months (range 6–40). All patients
were considered non-progressive after two cycles of induction
platinum-based chemotherapy. Among them, 32 received sequen-
tial RT after two more cycles (total= 4 cycles) of chemotherapy,
while 29 were treated with concurrent chemoradiation. All patients
but one, who discontinued treatment due to a decline in perfor-
mance status, finished the scheduled course, with a median of
42 days (range, 42–45 days). One patient died prematurely from
non-cancer and non-treatment-related causes within 3 months
after completion of the radiation course. Details on the baseline
disease, patients, and treatment characteristics are summarized in
Table 1.
TOXICITY
No Grade ≥4 acute and late toxicity was reported. Acute Grade 3
treatment-related pneumonitis was detected in 10%. In all cases,
acute lung toxicity developed 2–4 months after the completion
of treatment and resolved within 7 months. Two patients, both
receiving the concurrent schedule, developed a Grade 3 acute
esophagitis. The overall incidence of late Grade 3 lung toxicity was
5%. No patients experienced a Grade 3 late esophageal toxicity.
LOCAL CONTROL AND SURVIVAL
Among 59 patients evaluable for local control, the overall response
rate was 54% (6% CR, 48% PR). Stable disease was observed in
Table 1 | Baseline characteristics.
Value
PATIENTS CHARACTERISTICS
N Patients 61
Age (year) 67 (Range 40–78)
Sex
Mal 46 (75.4%)
Female 15 (24.6%)
COPD
Yes 39 (64%)
No 22 (36%)
WHO-PS
0 22 (36%)
1 31 (50.8%)
2 8 (13.2%)
Smokers
Never 7 (11.4%)
Quit 46 (75.4%)
Current 8 (13.2%)
DISEASE CHARACTERISTICS
Type of carcinoma
Adenocarcinoma 31 (50.8%)
Squamous cell 23 (37.8%)
Unspecified NSCLC 7 (11.4%)
Stage (TNM sixth edition) IIIA 35 (57.4%)
IIIB 26 (42.6%)
Median GTV size (cc) 81.8 (5.9–598.8)
Tumor location
Upper-middle lobes 47 (77%)
Inferior lobes 14 (23%)
TREATMENT CHARACTERISTICS
Chemotherapy timing
Induction All (100%)
Sequential 32 (52.5%)
Concurrent 29 (47.5%)
Drugs in sequential schedule
Cisplatin-gemcitabine 28 (87.5%)
Carboplatin based 4 (12.5%)
Drugs in concurrent schedule
Cisplatin-vinorelbine 29 (100%)
Total radiation dose 67.95 Gy (64.5–71.3 Gy)
Median OTT (days) 42 (42–45)
20%. Progression was documented in the remaining patients. The
median survival duration was 18.6 months in the sequential group
and 24.1 months in the concomitant group. A summary of the
analysis of patterns of failure is provided in Figure 1. One-year
and 2-year OS rate was 77 and 53% respectively for all patients
(Figure 2), 43% of whom were stage IIIB.
DISCUSSION
The renewed interest in the adoption of dose escalated regimens
has recently prompted the RTOG to open a randomized Phase III
trial, RTOG 0617 (18), to determine whether chemo-radiotherapy
with a higher radiation dose (74 Gy) improved overall survival
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FIGURE 1 | Pattern of failure.
FIGURE 2 | Overall survival for all patients.
compared with the current standard dose (60 Gy). Unexpectedly,
early findings (19), demonstrated that the higher dose of radiation
did not improve overall survival, and the study was closed to fur-
ther participant enrollment in the high-dose arm. In absence of a
difference between the toxicity rates between the two groups, it can
be speculatively argued that at least two factors may be advocated
for this disappointing outcome: (1) a higher risk of death related to
the effects on the normal lungs and perhaps the heart from high-
dose three dimensional conformal radiotherapy (3D-CRT) and
IMRT; (2) the protraction of the overall treatment time beyond
6 weeks in the high-dose arm, that might have favored tumor
repopulation. These poor results warrant the radioncological com-
munity to move a step backwards in the dose escalated approach.
However the path for dose escalation should not be abandoned
since local failure following concurrent chemotherapy and normo-
fractionated radiation therapy for patients with stage III NSCLC
approximates 85% (20), and the effect of higher radiation doses on
survival is shown to be independent of whether chemotherapy is
given (21). Thus, RT dose intensity remains important despite the
establishment of chemotherapy in Stage III NSCLC, ensuring a 4%
relative improvement in survival and 3% relative improvement in
loco-regional control for every 1 Gy BED increase (22). Over last
decade, radiotherapy schedules other than conventional fraction-
ation have been explored for dose intensification in unresectable
NSCLC: hyperfractionation has been investigated with promising
results and its efficacy has been substantiated in a Meta-Analysis of
Radiotherapy in Lung Cancer (MAR-LC) (23) conducted on 2000
patients affected with NSCLC that found that modified fraction-
ation (accelerated or hyperfractionated radiotherapy) improved
overall survival as compared to conventional radiotherapy, result-
ing in an absolute benefit of 2.5% (8.3–10.8%) at 5 years. Although
increasing the RT dose intensity by accelerating the time may rep-
resent a suitable strategy, its application in the clinical practice
may be challenging and limited by the logistic difficulties of treat-
ing patients multiple times in a day and an expected rates of greater
acute esophageal toxicity. On the other hand, the administration
of higher daily doses (hypofractionated RT) would be certainly
be more attractive, allowing to complete the treatment in fewer
fractions, but has long been discouraged given some concerns on
the potentially increased late adverse effects. Mehta et al. (9) have
developed a dose per fraction escalation schedule in NSCLC using
advanced radiotherapy delivery technologies. The strength of this
approach is the capability of escalating the dose by moderately
increasing the dose per fraction without prolonging the duration
of the treatment course beyond 6 weeks – which might counter-
act the benefit of dose escalation allowing time for the tumor to
begin re-growing. We implemented this alternative strategy in the
context of combined chemo-radiotherapy and we reported 10%
Grade 3 acute lung toxicity, which is consistent with the 8 and
11% encountered by others (24–26) and even lower than major
treatment-related pneumonitis rates observed in some recent tri-
als that have assessed hypofractionated RT regimens in association
with chemotherapy (27, 28). Our findings confirm that moderate
hypofractionation using IGRT techniques, that help to reduce the
total irradiated volume,might not actually increase the risk of radi-
ation pneumonitis in typical “parallel” organs such as the healthy
lungs – with an expected marked volume effect – despite the tumor
fractionation sensitivity is smaller than that of the critical normal
tissue (29). The time course of acute lung toxicity reflected the
typical pattern of behavior of the classical radiation pneumonitis,
having developed 2–4 months after the completion of radiation
and resolved without sequelae within 7 months (30). Then, in two
patients who experienced a Grade 3 acute esophagitis, the maxi-
mum time of discontinuation of treatment did not exceed 3 days,
thus resulting in a very short treatment break. Late toxicity was
mild, with no patients experiencing a>G2 esophagitis. Outcomes
in terms of local tumor control and survival seem to compare
favorably with prospective data from phase II trials (25, 31, 32)
addressing the role of concurrent chemotherapy either in combi-
nation with modern radiotherapy techniques, or in the setting of
dose escalation for various hypofractionation schemes in locally
advanced inoperable NSCLC (33–36) (Table 2).This study does
not lead to any definitive conclusion on the correlation between
overall survival and dose level, but a strong relationship would be
expected given that higher dose is known to improve local control.
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Table 2 | Comparison of reported series of dose escalation or dose escalated hypofractionated radiotherapy in inoperable non-small cell lung
cancer.
Author Patients with
stage III NSCLC
RT dose Fraction Toxicity Outcomes
Kong (33) 60 63–103 Gy 2.15 Gy – 5-Years OS, 13%
Median survival, 19 months
Bradley (34) 83 71–90 Gy 2.10 Gy No Group 3–4 acute esophagitis 3-Years OS, 26% (IIIA)
Acute Group ≥3 pneumonitis 6% 15% (IIIB)
Late Group ≥3 esophagitis 0–8%
Late Group ≥3 pneumonitis 0–16%
Belderbos (35) 42 60–94 Gy 2.25 Gy No Group 3–4 acute esophagitis 2-Years OS, 24–40% (GTV </≥75 cm3)
Acute Group ≥3 pneumonitis 35% Median survival, 17 months
Late Group ≥3 pneumonitis 57%
1 Case of late Group 5 esophagitis
Bral (36) 40 70.5 Gy 2.35 Gy Acute Group 5 pneumonitis 5% 1-Year OS, 65%
Acute Group 3 esophagitis 2.5% 2-Years OS, 27%
Late Group 3 pneumonitis 16% Median survival, 17 months
No Group 3–4 late esophagitis
Adkison (24) 36 57–80.5 Gy 2.28–3.22 Gy No Group 3–4 acute toxicities 2-Years OS, 46.8%
Acute Group 2 esophagitis 13% Median survival, 18 months
Acute Group 2 pneumonitis 13%
Current 61 67.5–68.4 Gy 2.25–2.28 Gy Acute Group 3 esophagitis 3% 1-Year OS, 77%
Acute Group 3 pneumonitis 12% 2-Years OS, 53%
Late Group 3 pneumonitis 7% Median survival:18.6 months (seq Group)
No Group 3–4 late esophagitis 24.1 Months (conc group)
Notwithstanding its retrospective nature and a potential bias
due to the accrual of selected (responders-only) patients to the
induction chemotherapy, our findings show that high biologically
effective dose delivered in a standard time frame may be safely
administered with or without chemotherapy, provided that highly
conformal radiotherapy techniques are used. More robust clinical
trials are needed to confirm this strategy.
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